17,726 Shares in Zoetis Inc. $ZTS Bought by Fideuram Asset Management Ireland dac

Fideuram Asset Management Ireland dac purchased a new position in shares of Zoetis Inc. (NYSE:ZTS) during the fourth quarter, Holdings Channel.com reports. The fund purchased 17,726 shares of the company’s stock, valued at approximately $2,230,000.

A number of other hedge funds have also recently added to or reduced their stakes in the company. Brighton Jones LLC lifted its holdings in Zoetis by 180.4% during the fourth quarter. Brighton Jones LLC now owns 4,629 shares of the company’s stock valued at $754,000 after purchasing an additional 2,978 shares in the last quarter. Empowered Funds LLC lifted its holdings in Zoetis by 6.2% during the first quarter. Empowered Funds LLC now owns 11,293 shares of the company’s stock valued at $1,859,000 after purchasing an additional 657 shares in the last quarter. Intech Investment Management LLC lifted its holdings in Zoetis by 17.2% during the first quarter. Intech Investment Management LLC now owns 8,347 shares of the company’s stock valued at $1,374,000 after purchasing an additional 1,224 shares in the last quarter. Sivia Capital Partners LLC lifted its holdings in Zoetis by 73.8% during the second quarter. Sivia Capital Partners LLC now owns 3,348 shares of the company’s stock valued at $522,000 after purchasing an additional 1,422 shares in the last quarter. Finally, Glenview Trust co lifted its holdings in Zoetis by 11.8% during the second quarter. Glenview Trust co now owns 4,780 shares of the company’s stock valued at $745,000 after purchasing an additional 506 shares in the last quarter. 92.80% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other Zoetis news, Director Michael B. Mccallister bought 3,000 shares of Zoetis stock in a transaction dated Monday, May 11th. The stock was acquired at an average cost of $77.76 per share, for a total transaction of $233,280.00. Following the completion of the transaction, the director directly owned 24,524 shares of the company’s stock, valued at approximately $1,906,986.24. This represents a 13.94% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, Director Frank A. Damelio bought 6,650 shares of Zoetis stock in a transaction dated Wednesday, May 13th. The stock was acquired at an average price of $75.39 per share, with a total value of $501,343.50. Following the completion of the transaction, the director directly owned 21,458 shares of the company’s stock, valued at approximately $1,617,718.62. The trade was a 44.91% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders acquired 11,650 shares of company stock worth $886,384 over the last three months. Insiders own 0.22% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have issued reports on ZTS. Stifel Nicolaus decreased their price objective on shares of Zoetis from $105.00 to $95.00 and set a “hold” rating on the stock in a report on Friday, May 22nd. Citigroup decreased their price objective on shares of Zoetis from $145.00 to $112.00 and set a “buy” rating on the stock in a report on Monday, May 18th. Argus reaffirmed a “hold” rating on shares of Zoetis in a report on Wednesday. UBS Group decreased their price objective on shares of Zoetis from $130.00 to $99.00 and set a “neutral” rating on the stock in a report on Friday, May 8th. Finally, William Blair reaffirmed an “outperform” rating on shares of Zoetis in a report on Monday, March 2nd. Six analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $133.92.

Key Headlines Impacting Zoetis

Here are the key news stories impacting Zoetis this week:

• Positive Sentiment: Zoetis presented at the Stifel Jaws & Paws Conference, which may have helped keep some investor attention on the company’s long-term animal health growth story. Zoetis Inc. (ZTS) Presents at Stifel Jaws & Paws Conference 2026 Transcript
• Neutral Sentiment: Brokerage coverage now shows a consensus “Hold” rating on Zoetis, suggesting analysts see limited near-term upside or downside from current levels. Zoetis Inc. (NYSE:ZTS) Receives Consensus Rating of “Hold” from Brokerages
• Negative Sentiment: Argus Research downgraded Zoetis, adding to concerns that Wall Street’s view on the stock is softening. Argus Research downgrades Zoetis (ZTS)
• Negative Sentiment: Multiple law firms announced or promoted a securities class action tied to Zoetis, which can weigh on sentiment because it raises legal and reputational risk for the company. ZTS INVESTOR ALERT: Zoetis Inc. Investors with Substantial Losses Have Opportunity to Lead the Zoetis Class Action Lawsuit

Zoetis Price Performance

Shares of NYSE ZTS opened at $77.81 on Friday. The firm has a 50-day simple moving average of $104.29 and a 200-day simple moving average of $117.03. The stock has a market capitalization of $32.62 billion, a price-to-earnings ratio of 12.90, a price-to-earnings-growth ratio of 1.28 and a beta of 0.87. The company has a quick ratio of 1.91, a current ratio of 3.15 and a debt-to-equity ratio of 2.80. Zoetis Inc. has a 52 week low of $72.38 and a 52 week high of $172.23.

Zoetis (NYSE:ZTS) last issued its earnings results on Thursday, May 7th. The company reported $1.53 EPS for the quarter, missing analysts’ consensus estimates of $1.60 by ($0.07). The business had revenue of $2.26 billion during the quarter, compared to analyst estimates of $2.30 billion. Zoetis had a net margin of 27.80% and a return on equity of 66.85%. Zoetis’s quarterly revenue was up 2.9% on a year-over-year basis. During the same quarter last year, the company earned $1.48 earnings per share. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. On average, equities analysts predict that Zoetis Inc. will post 6.89 earnings per share for the current fiscal year.

Zoetis Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 1st. Stockholders of record on Monday, July 20th will be given a $0.53 dividend. This represents a $2.12 dividend on an annualized basis and a dividend yield of 2.7%. The ex-dividend date is Monday, July 20th. Zoetis’s dividend payout ratio is 35.16%.

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.